These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 7987822)
1. Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient. Bubley GJ; Ogata GK; Dupuis NP; Teicher BA Cancer Res; 1994 Dec; 54(24):6325-9. PubMed ID: 7987822 [TBL] [Abstract][Full Text] [Related]
2. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells. Brandt TY; Ali-Osman F Toxicol Appl Pharmacol; 1997 Mar; 143(1):22-9. PubMed ID: 9073588 [TBL] [Abstract][Full Text] [Related]
3. Postlabeling detection of DNA adducts of antitumor alkylating agents. Zhou GH; Teicher BA; Frei E Cancer Chemother Pharmacol; 1996; 38(1):71-80. PubMed ID: 8603455 [TBL] [Abstract][Full Text] [Related]
4. Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction. Oshita F; Eastman A Oncol Res; 1993; 5(3):111-8. PubMed ID: 8260747 [TBL] [Abstract][Full Text] [Related]
5. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection. Yanow SK; Purcell LA; Spithill TW Mol Biochem Parasitol; 2006 Jul; 148(1):52-9. PubMed ID: 16597469 [TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin. Bhuyan BK; Smith KS; Kelly RC; Adams EG; Abraham I; Sampson KE Cancer Res; 1993 Mar; 53(6):1354-9. PubMed ID: 8443816 [TBL] [Abstract][Full Text] [Related]
7. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Gorczyca W; Gong J; Ardelt B; Traganos F; Darzynkiewicz Z Cancer Res; 1993 Jul; 53(13):3186-92. PubMed ID: 8319228 [TBL] [Abstract][Full Text] [Related]
8. Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. Murata M; Suzuki T; Midorikawa K; Oikawa S; Kawanishi S Free Radic Biol Med; 2004 Sep; 37(6):793-802. PubMed ID: 15304255 [TBL] [Abstract][Full Text] [Related]
9. The alkylating antitumor drug tallimustine does not induce DNA repair. Rossi R; Montecucco A; Capolongo L; Mezzina M; Chevallier-Lagente O; Sarasin A; Ciarrocchi G Anticancer Res; 1996; 16(6B):3779-83. PubMed ID: 9042257 [TBL] [Abstract][Full Text] [Related]
10. The DNA minor groove-alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells. Cao PR; McHugh MM; Melendy T; Beerman T Mol Cancer Ther; 2003 Jul; 2(7):651-9. PubMed ID: 12883038 [TBL] [Abstract][Full Text] [Related]
11. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Frost P; Abbruzzese JL; Hunt B; Lee D; Ellis M Cancer Res; 1990 Aug; 50(15):4572-7. PubMed ID: 1695122 [TBL] [Abstract][Full Text] [Related]
12. Mutation spectra induced by adozelesin in the supF gene of human XP-A fibroblasts. Lee SY; Pfeifer GP; Lee CS Arch Pharm Res; 2010 Apr; 33(4):633-6. PubMed ID: 20422374 [TBL] [Abstract][Full Text] [Related]
14. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280 [TBL] [Abstract][Full Text] [Related]
15. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Smith KS; Folz BA; Adams EG; Bhuyan BK Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669 [TBL] [Abstract][Full Text] [Related]
16. In vivo mutagenesis induced by CC-1065 and adozelesin DNA alkylation in a transgenic mouse model. Monroe TJ; Mitchell MA Cancer Res; 1993 Dec; 53(23):5690-6. PubMed ID: 8242625 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588 [TBL] [Abstract][Full Text] [Related]
18. High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines. Fritz G; Hengstler JG; Kaina B Cancer Res; 1997 Feb; 57(3):454-60. PubMed ID: 9012473 [TBL] [Abstract][Full Text] [Related]
19. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. Chen G; Zeller WJ; Todorov DK Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496 [TBL] [Abstract][Full Text] [Related]
20. Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity. Woynarowski JM; Napier C; Trevino AV; Arnett B Biochemistry; 2000 Aug; 39(32):9917-27. PubMed ID: 10933811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]